Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $49.92M fell 29.6% year over year, ahead of the -37.9% change in trailing-twelve-month research & development. Sequentially, it fell 0.4% from the prior quarter. Over 3 fiscal years it compounded at -38.6% a year.

Context

  • Research & development amounted to 143.3% of revenue in FY2025, down 43.5 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -29.6% holds above the trailing-twelve-month pace of -37.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$49.92M-0.4% QoQ
Last fiscal yearDec 2025
$243.77M-42.5% YoY
LTMMar 2026
$222.77M-37.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.6%——
1 year-42.5%——
3-year CAGR-38.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
243.77M USD
Year-over-year change
-42.5%
4-year CAGR
-32.1%

Research & Development vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.9% is the lowest of 10, against a peer median of +9.2%.
  • Research & development amounts to 157.6% of revenue for DNA, versus a peer median of 112.7%.
DNA Competitors
Research & Development for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
ARVNArvinas, Inc.LTM Mar 2026$254.4M USD-28.3%-3.5%284.6%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M USD-19.7%+0.6%63.8%
REPLReplimune Group, Inc.LTM Dec 2025$223.39M USD+26.2%+32.9%—
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$222.77M USD-37.9%-38.6%157.6%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M USD+5.2%+71.4%—
MGTXMeiraGTx Holdings plcLTM Mar 2026$128.82M USD+9.2%+14.8%161.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$101.27M USD+35.7%+54.7%—
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$21.15M USD+13.2%+8.3%10.1%
Peer median (excluding DNA) —+9.2%+8.3%112.7%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.